Xiamen Amoytop Biotech Adjusts Valuation Amidst Market Challenges and Strong Financial Metrics

Xiamen Amoytop Biotech Co., a prominent player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects a shift in the company's valuation metrics, which are critical indicators of its market position and financial health. The stock's P/E ratio stands at 23, while the Price to Book Value is recorded at 6.43. Additionally, the EV to EBIT and EV to EBITDA ratios are noted at 18.82 and 17.10, respectively. The company also showcases a PEG ratio of 1.56, indicating its growth relative to its valuation. Notably, Xiamen Amoytop has maintained a robust Return on Capital Employed (ROCE) of 43.98% and a Return on Equity (ROE) of 27.84%, underscoring its effective use of capital. Despite a challenging quarter in March 2026, the company has consistently reported positive results over the last 18 quarters. With net sales reaching CNY 1,216.02 million and an operating profit of CNY 472.2 million, Xiamen Amoytop continues to demonstrate resilience in its operations. However, it has faced headwinds, underperforming the market with a return of -9.14% over the past year, contrasting sharply with the China Shanghai Composite's return of 22.49%. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.